8 rules to combat medical misinformation. World View from CT_Bergstrom
Vaccination, hydroxychloroquine, masks and long COVID — all have become politicized, leading to the distortion of medical research during the COVID-19 pandemic and highlighting the severe harm that can accrue from medical misinformation and disinformation.
Second, avoid creating hype around your work or making tenuous claims about its significance. Although this sounds obvious, abuses are sadly common. Research in animal models should not be accompanied by incautious claims about human applications; in the absence of causal information, correlations should not be taken to suggest causation; and modeling should never overstate its scope. Be meticulous in specifying sources of uncertainty.
Fifth, if you intend to post a preprint, understand how preprints are received by the public and the media. Biomedical papers often have immediate public relevance and preprint servers have been invaluable for rapid communication during the COVID-19 pandemic, but the press and public do not necessarily understand their provisional nature.
South Africa Latest News, South Africa Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gut microbiome correlates of response and toxicity following anti-CD19 CAR T cell therapy - Nature MedicineIn an analysis of adult patients with hematologic malignancies who received anti-CD19 chimeric antigen receptor T cell therapy, baseline gut microbiome composition was correlated with clinical response and treatment with broad-spectrum antibiotics in the four weeks prior to infusion was associated with worse survival and increased neurotoxicity.
Read more »
Fixing America’s eating habits with effective stakeholder collaborations - Nature MedicineNews and Views: Pao-Hwa Lin and Crystal Tyson DukeHealth discuss new data that show how effective collaborations among stakeholders — such as researchers and food retailers — could help fix America's eating habits. DukeU
Read more »
Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial - Nature MedicinePresented at ASH21: In the phase 2 ZUMA-12 trial, first-line treatment with axi-cel CARTcells exhibited a high complete response rate and a manageable safety profile in adults with high-risk large B cell lymphoma MDAndersonNews MoffittNews ASH22
Read more »
Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma - Nature MedicineBiallelic loss of BCMA caused a patient with myeloma to relapse after treatment with anti-BCMA CARTcells in the KarMMa trial. Baseline heterozygous BCMA deletions might be a risk factor for treatment resistance immunotherapy MMsm ASH22
Read more »
Molecular basis for DNA recognition by the maternal pioneer transcription factor FoxH1 - Nature CommunicationsFoxH1 is an essential maternal pioneer factor during embryonic development. Here, the authors present several FoxH1—DNA structures that reveal the molecular basis for FoxH1 binding specificity and pioneer factor activity.
Read more »
Pompe disease treated before birth - Nature BiotechnologyIn Brief: For the first time, clinicians successfully treat an unborn child with Pompe disease, a rare autosomal recessive metabolic disorder
Read more »